ATMPs...or Advanced Therapeutic Medicinal Products, are the "next big thing" in the world of #Pharma. If you are in the space, the big ones you hear most about are Cell & Gene Therapy and...lately...mRNA vaccines (thank you COVID-19).
This world isn't as simple as 2 or 3 therapies...it's more than that. Investment in Cell&Gene Therapy has been setting records with $20 and $23 Billion in the last 2 years alone. This is kind of a big deal.
Jake Adams, from CRB, joins me to discuss this and also the world of #RNA modulating therapies (not all as well known as mRNA Vaccines).
We discuss what makes these different therapies unique, what makes them effective, and more. Also a few rabbit trails including how did Jake turn into a go-to man for RNA as a young engineer. So listen up... :)
Check at Jake on LinkedIn!
Want to learn more about investment into the Cell & Gene Space?
CGT 2022 Investment Outlook
Learn about Oligonucleotides HERE!
Quick overview about TPDs HERE!